• The subject voluntarily participates in this study and signs the informed consent form;

• Age ≥18 years and ≤75 years;

• Expected survival time ≥3 months;

• ECOG performance status score of 0-1;

• Patients with recurrent or metastatic cervical cancer or endometrial cancer confirmed by histopathology and/or cytology;

• Archived tumor tissue samples from the primary or metastatic lesions within the past 3 years must be provided for PD-L1 and other testing;

• Must have at least one measurable lesion as defined by RECIST v1.1;

• Organ function levels must meet the requirements;

• Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, and the serum or urine pregnancy test must be negative. Patients must not be lactating. All enrolled patients must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.